Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 8Breast Neoplasms 7Endometrial Neoplasms 5Prostatic Neoplasms 4Neoplasms 4Triple Negative Breast Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Cholangiocarcinoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostate 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1fluorodopa F 18 1cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × olaparib × 30 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡